Navigation Links
URMC and Temple announce drug discovery partnership
Date:8/18/2011

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

"This is a perfect marriage of the world class drug discovery and medicinal chemistry programs of Temple University with the strong biomedical expertise of URMC and its faculty," said Stephen Dewhurst, Ph.D., chair of the URMC Department of Microbiology and Immunology. "I am excited by the opportunities this creates to explore innovative therapeutic approaches and targets."

"We are pleased and excited to establish this relationship with the University of Rochester Medical Center and its scientists and faculty," said Magid Abou-Gharbia, Ph.D., Director of Temple University's Moulder Center for Drug Discovery Research, based at the School of Pharmacy. "The disease program areas of URMC overlap significantly with those of the Moulder Center. The two organizations bring complementary experience and skills to the table and the combination of the two will undoubtedly lead to many new drug discovery projects and increase the chances of identifying new drugs for treating unmet medical needs."

Abou-Gharbia who previously worked as senior vice president of Discovery Research at Wyeth for 26 years has led the Moulder Center for Drug Discovery Research since its creation in 2008. The Center, which is located at Temple University in Philadelphia, is home to a unique, state-of-the-art laboratory that brings together pharmaceutical talent, instrumentation, and software to create one of the nation's top centers for integrated drug research.

The partnership reflects a growing trend in medical research in which academic institutions have become more directly involved in the drug discovery process, a role that has historically been filled by the pharmaceutical and biotech industries. As drug companies cut back on in-house research and development and become more risk-averse, they are increasingly looking to universities to conduct the early stage research necessary to identify promising new discoveries. For academic institutions, this means playing a more active role in identifying and guiding new compounds from the earliest stages of research along the path to becoming a new drug.

The partnership complements URMC's strength in fundamental biomedical research; specifically, identifying molecular and genetic "targets" that trigger disease. Over the last five years, the University of Rochester has received more than $1.9 billion in external research funding much of it focused in the areas of cancer, cardiovascular disease, neuromedicine, musculoskeletal disease, and immunology and infectious disease. The more recently established Moulder Center has already received over $10 million dollars in funding from private donations, federal grants, contract research and a recent Temple University Drug Discovery Research Initiative.

The agreement enables scientists at the two institutions to collaborate and move these discoveries to the next stage of research by identifying compounds that act upon these new targets and may ultimately form the basis for new therapeutics. URMC scientists will work with Moulder Center's medicinal chemistry and other drug development capabilities to rapidly screen large numbers of compounds to identify novel drug candidates that can undergo a battery of pre-clinical tests in the lab and in animal models necessary to ensure that they are stable, not toxic, and act as intended.

Some 30 URMC research projects have already been identified as potential candidates for this collaboration. These include novel approaches that could lead to new treatments for bacterial pathogens such as Methicillin-Resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii, which are notorious for their ability to evade conventional drug treatments and are widely regarded as two of the most important bacterial threats to health. Other ongoing URMC research is aimed at developing treatments for fungal diseases caused by Candida albicans and Cryptococcus neoformans, pathogens that affect premature infants, patients receiving cancer chemotherapy and organ transplants, and those living with HIV/AIDS.


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. First Ever Virtual Autism Conference Featuring Temple Grandin and 16 speakers to discuss: “Things To Know About Autism” April 10th-11th.
2. Temple receives $3.7 million to study parenting styles effect on childhood obesity
3. Temple-led study finds widening gap between distracted driving and legislation
4. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
5. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
6. Connecture, Inc. Announces Partnership with MedicareCRM
7. Chiquita Announces Support for School Salad Bar Campaign
8. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
9. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
10. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
11. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users ... beautiful 3D slideshow with complete ease," said Christina Austin - CEO of Pixel Film ... in the FCPX timeline. Presets include scenes with one, three, four or ...
(Date:1/21/2017)... ... , ... Salveo for life, a company that distributes an effervescent lime-flavored drink ... as part of its presence to expand its market reach. , Using a formula ... of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to ... the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is ... at 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam ... rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Laboratory Testing Market By Type of Test (Tumor, Clinical Chemistry, ... By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast ... ... destination for healthcare services, market segments, especially clinical lab testing, ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug Manufacturers equities: ... A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. (NASDAQ: ... PTX ). These stocks belong to the Healthcare ... finishing near its session lows. As per a NASDAQ report, ... of health care companies in the S&P 500 also were ...
Breaking Medicine Technology: